Semaglutide & cardiovascular outcomes: the SELECT trial

SELECT: cardiovascular outcomes for a weight-loss drug

Published in 2023, SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, but without diabetes, and followed them for a mean of about 40 months. Semaglutide 2.4 mg reduced the primary composite endpoint — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — by 20% (hazard ratio 0.80) versus placebo. This was the first trial to show a weight-management GLP-1 prevents cardiovascular events, independent of diabetes.

Blood pressure, lipids, and inflammation

Beyond events, semaglutide moves cardiometabolic markers. Across the STEP program and real-world cohorts, patients saw meaningful reductions in systolic blood pressure (roughly 5–6 mmHg), triglycerides, LDL cholesterol, HbA1c, and C-reactive protein — an inflammation marker linked to cardiovascular risk. These changes are largely weight-loss mediated.

What SELECT does and doesn't prove

SELECT was a landmark, but reading it precisely matters. It enrolled people who already had established cardiovascular disease plus overweight or obesity, and specifically excluded people with diabetes. That means its 20% event reduction applies most directly to secondary prevention — reducing a second event in people who've already had cardiovascular disease — rather than to primary prevention in otherwise healthy people carrying extra weight. It's also worth noting the event reduction is larger than weight loss alone would fully explain in some analyses, suggesting benefits through inflammation, blood pressure, and the vasculature directly. Critically, SELECT studied the FDA-approved brand product; its findings cannot simply be assumed to transfer to compounded semaglutide, which has no comparable outcomes trial.

The financial case for treating obesity as cardiovascular disease

A cardiovascular event — heart attack or stroke — can cost tens of thousands of dollars acutely and far more over time. A patient who avoids one is generating savings that dwarf even brand semaglutide's ~$16,000 annual cost, let alone a $1,740 flat-rate compounded program. This is the argument payers are slowly accepting: treating obesity aggressively can be cheaper than treating its downstream disease. If you have established cardiovascular disease alongside overweight or obesity, your prescriber can now cite a 17,000-patient trial to a medical reviewer — the strongest lever in many prior-authorization requests.

Frequently asked questions

Using SELECT in an insurance and coverage conversation

The SELECT trial changed more than the clinical understanding of semaglutide — it changed the insurance argument, and knowing how to use it can be worth thousands of dollars for the right patient. Before SELECT, insurers often treated obesity as a lifestyle condition and weight-management drugs as cosmetic, an easy basis for denial. After SELECT, semaglutide has strong evidence that it prevents heart attacks and strokes in people with established cardiovascular disease and excess weight. For a patient with that profile, this transforms a prior-authorization request from a plea into an evidence-backed medical-necessity argument. The practical mechanics: your prescriber documents the qualifying cardiovascular condition with the appropriate diagnosis codes, references the SELECT outcome in the medical-necessity letter, and frames semaglutide as cardiovascular risk reduction rather than weight loss alone. If the first request is denied, an internal appeal citing the specific trial evidence and the plan own coverage criteria is the next step, followed by external review if needed. This path applies to the FDA-approved brand product, which is what insurance covers — compounded semaglutide is essentially never reimbursed, so the SELECT-based coverage argument is precisely the reason an insured cardiovascular patient should pursue brand coverage before defaulting to cash-pay compounded. The evidence that makes the brand worth pursuing is the same evidence that does not automatically transfer to the compounded product.

What SELECT means for everyday patients

For someone weighing semaglutide who does not have established cardiovascular disease, SELECT still carries a useful, if indirect, message: the same weight loss and metabolic improvements that reduced events in high-risk patients are the mechanisms working in anyone who responds to the drug. Lower blood pressure, better lipids, reduced inflammation, and improved glucose handling are not exclusive to the trial population; they accompany meaningful weight loss broadly. What SELECT does not do is license a claim that semaglutide prevents first-ever heart attacks in otherwise healthy people carrying extra weight, because that primary-prevention question was not what the trial tested. The practical takeaway is calibrated optimism: the cardiovascular benefits are real and now proven where risk is highest, they plausibly extend in softer form to lower-risk patients through the same pathways, and they strengthen the general case that treating obesity is treating a driver of downstream disease rather than a cosmetic concern. For the cost-conscious reader, the enduring point is that these are benefits of the FDA-approved product studied in the trial, so a patient who qualifies for coverage has a strong reason to pursue the brand rather than assume compounded is the only affordable path. Any decision about cardiovascular risk and which product fits belongs with your physician.

Using SELECT in an insurance and coverage conversation

The SELECT trial changed more than the clinical understanding of semaglutide — it changed the insurance argument, and knowing how to use it can be worth thousands of dollars for the right patient. Before SELECT, insurers often treated obesity as a lifestyle condition and weight-management drugs as cosmetic, an easy basis for denial. After SELECT, semaglutide has strong evidence that it prevents heart attacks and strokes in people with established cardiovascular disease and excess weight. For a patient with that profile, this transforms a prior-authorization request from a plea into an evidence-backed medical-necessity argument. The practical mechanics: your prescriber documents the qualifying cardiovascular condition with the appropriate diagnosis codes, references the SELECT outcome in the medical-necessity letter, and frames semaglutide as cardiovascular risk reduction rather than weight loss alone. If the first request is denied, an internal appeal citing the specific trial evidence and the plan own coverage criteria is the next step, followed by external review if needed. This path applies to the FDA-approved brand product, which is what insurance covers — compounded semaglutide is essentially never reimbursed, so the SELECT-based coverage argument is precisely the reason an insured cardiovascular patient should pursue brand coverage before defaulting to cash-pay compounded. The evidence that makes the brand worth pursuing is the same evidence that does not automatically transfer to the compounded product.

References

1. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023.
2. Wilding JPH, et al. STEP 1 cardiometabolic secondary endpoints. N Engl J Med. 2021.
3. Novo Nordisk. Wegovy Prescribing Information — cardiovascular indication.
4. SemaglutideGLPOne July 2026 price report.

Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.

Keep reading